Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer

M. A. Rudek, W. D. Figg, V. Dyer, W. Dahut, M. L. Turner, S. M. Steinberg, D. J. Liewehr, D. R. Kohler, J. M. Pluda, E. Reed

Research output: Contribution to journal › Article › peer-review